Influx Healthtech Ltd
₹
None%
- close price
About
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing.[1]
Key Points
- Market Cap ₹ 222 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 16.6
- Book Value ₹
- Dividend Yield %
- ROCE 60.2 %
- ROE 45.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Debtor days have increased from 79.1 to 113 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 76 | 100 | 105 | |
| 65 | 83 | 84 | |
| Operating Profit | 11 | 17 | 21 |
| OPM % | 14% | 17% | 20% |
| 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 3 |
| Profit before tax | 10 | 15 | 18 |
| Tax % | 26% | 25% | 25% |
| 7 | 11 | 13 | |
| EPS in Rs | |||
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 45% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 18 |
| Reserves | 12 | 23 | 18 |
| 1 | 0 | 0 | |
| 16 | 18 | 34 | |
| Total Liabilities | 28 | 41 | 70 |
| 6 | 14 | 19 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 22 | 27 | 52 | |
| Total Assets | 28 | 41 | 70 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 7 | 9 | 7 | |
| -5 | -8 | -9 | |
| 0 | -1 | -0 | |
| Net Cash Flow | 2 | 0 | -2 |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 66 | 58 | 113 |
| Inventory Days | 18 | 41 | 112 |
| Days Payable | 123 | 106 | 248 |
| Cash Conversion Cycle | -39 | -6 | -24 |
| Working Capital Days | 4 | 16 | 47 |
| ROCE % | 85% | 60% |
Documents
Annual reports
No data available.
Business Profile[1]
The company operates as a Contract Development and Manufacturing Organization (CDMO) catering to B2B clients in nutraceuticals, cosmetics, ayurvedic/herbal products, veterinary feed supplements, and homecare products.
Its core competency is offering end-to-end manufacturing services, including product formulation, development, regulatory support, and commercialization.